ticker,name,event,date_of_catalyst
TXNP,"Tonix Pharmaceuticals Holding Corp.","The FDA has assigned a PDUFA goal date of August 15, 2025, for TNX-102 SL, a product candidate for the management of fibromyalgia. This follows the submission of a New Drug Application (NDA) based on two statistically significant Phase 3 studies. The FDA has previously granted Fast Track designation to this drug, indicating its potential importance in treating this condition.(PDUFA date)",2025-08-15
ENLV,"Enlivex Therapeutics Ltd.","Enlivex Therapeutics plans to publicly release audited topline results for three-month key endpoints from its Phase I/II trial of Allocetra™ in knee osteoarthritis patients, focusing on safety and changes in knee pain and function.(phase 1/2 data readout)",2025-08-18
ENLV,"Enlivex Therapeutics Ltd.","Enlivex Therapeutics will host a webinar to present and discuss the 3-month topline results from the Phase IIa stage of its ENX-CL-05-001 trial evaluating Allocetra™ in patients with knee osteoarthritis.(Phase 2a readout)",2025-08-18
AAPG,"Ascentage Pharma Group International - American Depository Shares","Ascentage Pharma will present data on olverembatinib at the Evercore China Biotech Summit, focusing on its efficacy in treating CML with T315I mutations.(Phase 3 data readout)",2025-08-19
